Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL
Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Related Articles
Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
Better Together: Spatial Arrangement of Three Immune Cells Is Key to
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T…
11 new research advances from the past year
Researchers and clinicians at MD Anderson continue to lead the way in making new discoveries and leading groundbreaking studies that advance cancer research and bring…
Registration
Registration details for AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia
Key PointsThe prevalence of myeloid CHIP in patients with CLL was 12% in untreated and 24% in treated patients (85% with prior chemotherapy exposure).The p
Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes
Key PointsExtrinsic tenase complexes are present in saliva of persons with hemophilia A and absent in saliva of persons with FVII deficiency.Presence or ab
Welcome! You are invited to join a webinar: Post-ASH 2024 Myeloma highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading Myeloma experts present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current clinical…
Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes.
Following a recent update in to NCCN gGuidelines, Drs. Garcia- Manero and Swoboda introduce themselves and theirwill discussion about the changing landscape of lower-risk myelodysplastic…
3 Things You Should Know About Immunotherapy in DLBCL
Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia…
